Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes.
P Martijn Kolijn, Karl Smith-Byrne, Vernon Burk, Vivian Viallon, Matthew A Lee, Keren Papier, Ziqiao Wang, Anton W Langerak, Florentin Späth, Arjan Diepstra, Christina M Lill, Raul Zamora-Ros, Alessandra Macciotta, Amaia Aizpurua, Rosario Tumino
Abstract
Open AccessThis study aims to investigate the early stages of lymphoid malignancy pathogenesis and identify pre-diagnostic proteomic markers for lymphoma. Using the SomaScan-7K platform, we analyze 6412 unique plasma proteins in a case-cohort study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, comprising 4565 participants (484 incident lymphoid malignancy cases, median follow-up 9 years). We identify over 500 unique protein-lymphoid malignancy associations. Enriched pathways include viral protein interactions, cytokine signaling, B-cell receptor signaling, and NF-κB activation, reflecting key mechanisms in lymphoma pathogenesis. Cross-cohort validation of the top 20 FDR-significant proteins reveals concordant nominal significance for 70%-95% of the associations in the UK Biobank (Olink) and ARIC (SomaScan) studies. Time-stratified analyses reveals that a subset of these protein-lymphoma associations is evident over a decade before diagnosis. These findings highlight the potential of circulating proteomic markers in risk stratification, early diagnosis, and targeted prevention strategies for lymphoid malignancies.